Huntington's Disease of the Endocrine Pancreas: Insulin Deficiency and Diabetes Mellitus due to Impaired Insulin Gene Expression

In a transgenic mouse model of the neurodegenerative disorder Huntington's disease (HD), age-dependent neurologic defects are accompanied by progressive alterations in glucose tolerance that culminate in the development of diabetes mellitus and insulin deficiency. Pancreatic islets from HD transgenic mice express reduced levels of the pancreatic islet hormones insulin, somatostatin, and glucagon and exhibit intrinsic defects in insulin production. Intranuclear inclusions accumulate with aging in transgenic pancreatic islets, concomitant with the decline in glucose tolerance. HD transgenic mice develop an age-dependent reduction of insulin mRNA expression and diminished expression of key regulators of insulin gene transcription, including the pancreatic homeoprotein PDX-1, E2A proteins, and the coactivators CBP and p300. Disrupted expression of a subset of transcription factors in pancreatic beta cells by a polyglutamine expansion tract in the huntingtin protein selectively impairs insulin gene expression to result in insulin deficiency and diabetes. Selective dysregulation of gene expression in triplet repeat disorders provides a mechanism for pleiotropic cellular dysfunction that restricts the toxicity of ubiquitously expressed proteins to highly specialized subpopulations of cells.

[1]  C. Dina,et al.  Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. , 1999, The Journal of clinical investigation.

[2]  I. Kanazawa,et al.  PQBP-1, a novel polyglutamine tract-binding protein, inhibits transcription activation by Brn-2 and affects cell survival. , 1999, Human molecular genetics.

[3]  G. Coetzee,et al.  Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. , 2000, Human molecular genetics.

[4]  A. Williams,et al.  Hyperproinsulinaemia in patients with myotonic dystrophy , 1992, Diabetologia.

[5]  S. W. Davies,et al.  Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  R. Tjian,et al.  Analysis of Sp1 in vivo reveals mutiple transcriptional domains, including a novel glutamine-rich activation motif , 1988, Cell.

[7]  W. Rutter,et al.  Synergistic activation of the insulin gene by a LIM-homeo domain protein and a basic helix-loop-helix protein: building a functional insulin minienhancer complex. , 1992, Genes & development.

[8]  Dimitri Krainc,et al.  Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease , 2002, Science.

[9]  R. Tjian,et al.  DNA looping between sites for transcriptional activation: self-association of DNA-bound Sp1. , 1991, Genes & development.

[10]  K. Fischbeck,et al.  CREB-binding protein sequestration by expanded polyglutamine. , 2000, Human molecular genetics.

[11]  Chawnshang Chang,et al.  The Linkage of Kennedy’s Neuron Disease to ARA24, the First Identified Androgen Receptor Polyglutamine Region-associated Coactivator* , 1999, The Journal of Biological Chemistry.

[12]  D. Housman,et al.  Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Bonner-Weir,et al.  Regulatory factor linked to late-onset diabetes? , 1998, Nature.

[14]  Huda Y. Zoghbi,et al.  Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1 , 2000, Nature Neuroscience.

[15]  M. Montminy,et al.  Characterization of somatostatin transactivating factor-1, a novel homeobox factor that stimulates somatostatin expression in pancreatic islet cells. , 1993, Molecular endocrinology.

[16]  L. Farrer.  Diabetes mellitus in Huntington disease , 1985, Clinical genetics.

[17]  C A Ross,et al.  Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity , 2001, Science.

[18]  J. Habener,et al.  Development of diabetes mellitus in aging transgenic mice following suppression of pancreatic homeoprotein IDX-1. , 2001, The Journal of clinical investigation.

[19]  W. Clarke,et al.  Early-onset type-ll diabetes mellitus (MODY4) linked to IPF1 , 1997, Nature Genetics.

[20]  J. M. Boutell,et al.  Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. , 1999, Human molecular genetics.

[21]  R. Scharfmann.  Neurotrophin and neurotrophin receptors in islet cells. , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[22]  Allen,et al.  Missense mutations in the insulin promoter factor-1 gene predispose to type 2 diabetes , 1999, The Journal of clinical investigation.

[23]  D. Housman,et al.  Evidence for a recruitment and sequestration mechanism in Huntington's disease. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[24]  Arun J Sharma,et al.  p300 Mediates Transcriptional Stimulation by the Basic Helix-Loop-Helix Activators of the Insulin Gene , 1998, Molecular and Cellular Biology.

[25]  M. F. Perutz,et al.  Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats , 2001, Nature.

[26]  H. Lehrach,et al.  Folding of oligoglutamines: a theoretical approach based upon thermodynamics and molecular mechanics. , 1999, Journal of biomolecular structure & dynamics.

[27]  William N. Ross,et al.  Calcium Dynamics and Electrophysiological Properties of Cerebellar Purkinje Cells in SCA1 Transgenic Mice , 2001 .

[28]  A. Roses,et al.  Oligomerization of expanded-polyglutamine domain fluorescent fusion proteins in cultured mammalian cells. , 1997, Biochemical and biophysical research communications.

[29]  N. Douarin.  On the origin of pancreatic endocrine cells , 1988, Cell.

[30]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[31]  G. Finocchiaro,et al.  Glucose metabolism alterations in Friedreich's ataxia , 1988, Neurology.

[32]  P. Silver,et al.  Polyglutamine Expansions Proteolysis, Chaperones, and the Dangers of Promiscuity , 2000, Neuron.

[33]  E. Dumonteil,et al.  Differential Regulation of the Glucagon and Insulin I Gene Promoters by the Basic Helix-Loop-Helix Transcription Factors E47 and BETA2* , 1998, The Journal of Biological Chemistry.

[34]  Shihua Li,et al.  Cellular Defects and Altered Gene Expression in PC12 Cells Stably Expressing Mutant Huntingtin , 1999, The Journal of Neuroscience.

[35]  J. Habener,et al.  Glucagon Gene Transcription Activation Mediated by Synergistic Interactions of pax-6 and cdx-2 with the p300 Co-activator* , 1999, The Journal of Biological Chemistry.

[36]  J. Cha,et al.  Transcriptional dysregulation in Huntington’s disease , 2000, Trends in Neurosciences.

[37]  J. Habener,et al.  IDX‐1: a new homeodomain transcription factor expressed in rat pancreatic islets and duodenum that transactivates the somatostatin gene. , 1994, The EMBO journal.

[38]  S. W. Davies,et al.  Formation of polyglutamine inclusions in non-CNS tissue. , 1999, Human molecular genetics.

[39]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[40]  A. Bhattacharjee,et al.  A Low Voltage-Activated Ca2+ Current Mediates Cytokine-Induced Pancreatic β-Cell Death. , 1999, Endocrinology.

[41]  J. Schiefer,et al.  Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus , 2001, Behavioural Brain Research.

[42]  S. Hersch,et al.  Huntingtin aggregates may not predict neuronal death in Huntington's disease , 1999 .

[43]  S. Rusconi,et al.  Transcriptional activation modulated by homopolymeric glutamine and proline stretches. , 1994, Science.

[44]  M. Cnop,et al.  Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. , 2002, Diabetes.

[45]  S. Suhr,et al.  Intraneuronal Aggregate Formation and Cell Death after Viral Expression of Expanded Polyglutamine Tracts in the Adult Rat Brain , 2000, The Journal of Neuroscience.

[46]  W. Strittmatter,et al.  Polyglutamine Domain Proteins with Expanded Repeats Bind Neurofilament, Altering the Neurofilament Network , 1999, Annals of the New York Academy of Sciences.

[47]  M. Beal,et al.  Oxidative Stress in Huntington's Disease , 1999, Brain pathology.

[48]  K. Yamamoto,et al.  Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticoid receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[49]  S. Podolsky,et al.  Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease. , 1977, Gerontology.

[50]  J. Habener,et al.  Homeodomain Protein IDX-1 A Master Regulator of Pancreas Development and Insulin Gene Expression , 1997, Trends in Endocrinology & Metabolism.

[51]  Arun J Sharma,et al.  The NeuroD1/BETA2 Sequences Essential for Insulin Gene Transcription Colocalize with Those Necessary for Neurogenesis and p300/CREB Binding Protein Binding , 1999, Molecular and Cellular Biology.

[52]  H. Zoghbi,et al.  Identification of genes that modify ataxin-1-induced neurodegeneration , 2000, Nature.

[53]  P. Lacy,et al.  Method for the Isolation of Intact Islets of Langerhans from the Rat Pancreas , 1967, Diabetes.

[54]  O. Andreassen,et al.  Creatine Increases Survival and Delays Motor Symptoms in a Transgenic Animal Model of Huntington's Disease , 2001, Neurobiology of Disease.

[55]  Blair R. Leavitt,et al.  Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease , 2001, Science.

[56]  K. Yao,et al.  Bridge-1, a Novel PDZ-Domain Coactivator of E2A-Mediated Regulation of Insulin Gene Transcription , 1999, Molecular and Cellular Biology.

[57]  D. Housman,et al.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila , 2001, Nature.

[58]  A. Grierson,et al.  Polyglutamine repeat length influences human androgen receptor/c-Jun mediated transcription , 1999, Neuroscience Letters.

[59]  R. Tjian,et al.  A Glutamine-Rich Trail Leads to Transcription Factors , 2002, Science.

[60]  M. Hurlbert,et al.  Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. , 1999, Diabetes.

[61]  N. Weigel,et al.  Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. , 1999, Human molecular genetics.

[62]  J. Nevins,et al.  Huntingtin Is Present in the Nucleus, Interacts with the Transcriptional Corepressor C-terminal Binding Protein, and Represses Transcription* , 2002, The Journal of Biological Chemistry.

[63]  J. Habener,et al.  Insulinotropic Glucagon-like Peptide-1-mediated Activation of Non-selective Cation Currents in Insulinoma Cells Is Mimicked by Maitotoxin* , 1997, The Journal of Biological Chemistry.

[64]  S. W. Davies,et al.  From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[65]  J. Habener,et al.  Hedgehog Signaling Regulation of Homeodomain Protein Islet Duodenum Homeobox-1 Expression in Pancreatic β-Cells. , 2001, Endocrinology.

[66]  R. Moratalla,et al.  Pancreatic Homeodomain Transcription Factor IDX1/IPF1 Expressed in Developing Brain Regulates Somatostatin Gene Transcription in Embryonic Neural Cells* , 2000, The Journal of Biological Chemistry.

[67]  V. Grill,et al.  Overstimulation and beta-cell function. , 2001, Diabetes.

[68]  O. Andreassen,et al.  Nonlinear Decrease over Time in N‐Acetyl Aspartate Levels in the Absence of Neuronal Loss and Increases in Glutamine and Glucose in Transgenic Huntington's Disease Mice , 2000, Journal of neurochemistry.

[69]  A. Reiner,et al.  Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation. , 2001, Human molecular genetics.

[70]  H. Edlund,et al.  beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. , 1998, Genes & development.

[71]  R. Stein,et al.  Insulin Gene Transcription Is Mediated by Interactions between the p300 Coactivator and PDX-1, BETA2, and E47 , 2002, Molecular and Cellular Biology.

[72]  G I Bell,et al.  Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. , 2001, The New England journal of medicine.

[73]  S. Bonner-Weir,et al.  Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. , 2000, Diabetes.

[74]  P. Newsholme,et al.  Evidence for a sustained increase in clonal beta-cell basal intracellular Ca2+ levels after incubation in the presence of newly diagnosed Type-1 diabetic patient sera. Possible role in serum-induced inhibition of insulin secretion. , 2002, The Journal of endocrinology.

[75]  J. Habener,et al.  Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. , 2001, Diabetes.

[76]  D. Housman,et al.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[77]  J. B. Martin,et al.  Molecular basis of the neurodegenerative disorders. , 1999, The New England journal of medicine.

[78]  C A Ross,et al.  Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. , 2000, Human molecular genetics.

[79]  G. Reynolds,et al.  The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease , 2002, Journal of neurochemistry.

[80]  P. Kantoff,et al.  The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. , 1999, Urology.

[81]  J. Habener,et al.  Hedgehog signaling regulation of insulin production by pancreatic beta-cells. , 2000, Diabetes.

[82]  R. McKay,et al.  Differentiation of Embryonic Stem Cells to Insulin-Secreting Structures Similar to Pancreatic Islets , 2001, Science.